Application strategy of circulating tumor DNA in entire process of precision medicine for hepatocellular carcinoma
10.3760/cma.j.cn115610-20241224-00578
- VernacularTitle:循环肿瘤DNA在肝细胞癌精准医疗全程中的应用策略
- Author:
Mingda HE
1
;
Yuze YANG
;
Mingda WANG
;
Chao LI
;
Han WU
;
Tian YANG
Author Information
1. 海军军医大学基础医学院，上海 200433
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Circulating tumor DNA;
Diagnosis;
Therapeutic monitor-ing;
Prognostic assessment
- From:
Chinese Journal of Digestive Surgery
2025;24(1):86-92
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, emphasizing the utmost importance of early diagnosis, therapeutic monitoring, and pro-gnostic assessment. Circulating tumor DNA (ctDNA), as an innovative liquid biopsy biomarker, has demonstrated unique advantages in HCC management. The authors systematically summarized recent advances in the application of ctDNA for early diagnosis, therapeutic monitoring, and prognostic evaluation of HCC, focusing on its advantages and clinical application value in precision medicine.
